# Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

> **NCT02722512** · PHASE1 · TERMINATED · sponsor: **Ann & Robert H Lurie Children's Hospital of Chicago** · enrollment: 10 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Astrocytoma, Grade III
- Anaplastic Ependymoma
- Clear Cell Ependymoma
- Ependymoma

## Interventions

- **BIOLOGICAL:** Heat Shock Protein Peptide Complex-96 (HSPPC-96)
- **PROCEDURE:** Tumor Resection
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT02722512
- **Lead sponsor:** Ann & Robert H Lurie Children's Hospital of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2019-11-13
- **Final completion:** 2019-11-13
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Lack of substantial evidence for immune responses in response to vaccination.
- **Last updated:** 2025-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722512, "Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02722512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*